Recent Updates
Recently added Catalysts
PEPG Negative Sentiment Score: 20/100

PEPGEN (PEPG) ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Against PepGen and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. has filed a class action lawsuit against PepGen, Inc. (PEPG) for alleged misleading statements about its business and products during the Class Period from March 7, 2024, to March 3, 2025. The lawsuit claims that claims surrounding the PGN-EDO51 product and the CONNECT2 study were overstated, raising concerns about their effectiveness and safety. Investors who sustained losses and acquired PepGen securities during this period are advised to contact the law firm regarding their legal options. They must apply to be lead plaintiffs by August 8, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • PepGen is facing a class action lawsuit due to alleged false and misleading statements.
  • The CONNECT2 study is reportedly deficient, potentially jeopardizing FDA approval.
  • The company's product, PGN-EDO51, has displayed lower effectiveness and safety than claimed.
  • Investors are encouraged to contact attorneys for legal rights due to incurred losses.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In PepGen (PEPG) To Contact Them Directly To Discuss Their Options
If you purchased or acquired securities in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against PepGen, Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). Investors have until August 8, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) PGN-EDO51 was less effective and safe than Defendants had led investors to believe; (ii) the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired PepGen shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is the class action lawsuit against PepGen about?

The lawsuit alleges that PepGen made false statements about its business and the safety of its product PGN-EDO51.

When is the deadline to join the lawsuit against PepGen?

Investors have until August 8, 2025, to apply as lead plaintiffs in the lawsuit.

Who can I contact regarding the PepGen lawsuit?

You can contact Brandon Walker or Marion Passmore at Bragar Eagel & Squire, P.C.

Is there a fee to discuss my options regarding PepGen?

There is no cost or obligation to discuss your legal rights with the firm.

What is Bragar Eagel & Squire, P.C. known for?

The firm is recognized for representing investors in complex litigation, including securities cases.

Last updated: Aug 2, 2025